The therapeutic effects of ursodeoxycholic acid as an anti-apoptotic agent

Expert Opinion on Investigational Drugs

Volumn 10, Issue 7, 2001, Pages 1243-1253

  Rodrigues, C M P ^a   Steer, C J ^a  

^a UNIVERSITY OF LISBON   (Portugal)

Author keywords

Bile acids; Cholestasis; Hepatoprotection; Mitochondrial pathway of apoptosis; Neuroprotection

Indexed keywords

BILE ACID; URSODEOXYCHOLIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; BILE COMPOSITION; BIOCHEMISTRY; CELL DEATH; CELL MEMBRANE; CHOLESTASIS; CHOLESTATIC HEPATITIS; CLINICAL TRIAL; CONJUGATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; GALLSTONE; GALLSTONE DISSOLUTION; HUMAN; HUMAN CELL; HYDROPHILICITY; IMMUNE RESPONSE; IMMUNOREGULATION; LIVER CELL; LIVER FUNCTION; LIVER TRANSPLANTATION; MODULATION; MOLECULAR BIOLOGY; NONHUMAN; PATHOGENESIS; PRIMARY BILIARY CIRRHOSIS; RAT; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL; TREATMENT OUTCOME; WESTERN HEMISPHERE;

ANIMALS; APOPTOSIS; BILE ACIDS AND SALTS; CHOLESTASIS; HUMANS; MITOCHONDRIA; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; URSODEOXYCHOLIC ACID;

EID: 0034942512     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.7.1243     Document Type: Review

References (99)

1. Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years follow-up. A pilot study
2. Efficacy and safety of a combination of chenodeoxycholic acid and ursodeoxycholic acid for gallstone dissolution: A comparison with ursodeoxycholic acid alone
3. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?
4. Ursodeoxycholic acid in primary biliary cirrhosis: Results of a controlled double-blind trial
5. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis
6. Ursodeoxycholic acid in cholestasis: Potential mechanisms of action and therapeutic applications
7. A novel role of ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation
8. Ursodeoxycholic acid prevents cytochrome c release in apoptosis by inhibiting mitochondrial membrane depolarization and channel formation
9. Bilirubin and amyloid-beta peptide induce cytochrome c release through mitochondrial membrane permeabilization
10. Tauroursodeoxycholic acid partially prevents apoptosis induced by 3-nitropropionic acid: Evidence for a mitochondrial pathway independent of the permeability transition
11. Mechanism of cholestasis. 6. Bile acids in human livers with or without biliary obstruction
12. Mechanism of cholestasis. 5. Bile acids in normal rat livers and in those after bile duct ligation
13. Bile acid concentrations in human and rat liver tissue and in hepatocyte nuclei
14. Influence of hydroxylation and conjugation of bile salts on their membrane-damaging properties: Studies on isolated hepatocytes and lipid membrane vesicles
15. Hepatic injury induced by bile salts: Correlation between biochemical and morphological events
16. Conjugates of ursodeoxycholate protect against cholestasis and hepatocellular necrosis caused by more hydrophobic bile salts. In vivo studies in the rat
17. Mitochondrial membrane perturbations in cholestasis
18. Caspases: Enemies within
19. Apoptotic pathways: Paper wraps stone blunts scissors
20. Mechanism of cholestasis. 4. Structural and biochemical changes in the liver and serum in rats after bile duct ligation
21. Reduced activity of the electron transport chain in liver mitochondria isolated from rats with secondary biliary cirrhosis
22. Glycochenodeoxycholate-induced lethal hepatocellular injury in rat hepatocytes. Role of ATP depletion and cytosolic free calcium
23. Toxicity of bile acids on the electron transport chain of isolated rat liver mitochondria
24. Ursodeoxycholate (UDCA) inhibits the mitochondrial membrane permeability transition induced by glycochenodeoxycholate: A mechanism of UDCA cytoprotection
25. Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production
26. Cyclosporine and carnitive prevent the anoxic cell death of cultured hepatocytes by inhibiting the mitochondrial permeability transition
27. Modulation of the mitochondrial cyclosporine A-sensitive permeability transition pore by the proton electrochemical gradient. Evidence that the pore can be opened by membrane depolarization
28. Cholestasis confers resistance to the rat liver mitochondrial permeability transition
29. The proto-oncogene Bcl-2 and its role in regulating apoptosis
30. Generation of hydroperoxides in isolated rat hepatocytes and hepatic mitochondria exposed to hydrophobic bile acids
31. Vitamin E reduces oxidant injury to mitochondria and the hepatotoxicity of taurochenodeoxycholic acid in the rat
32. Effect of oxypurinol, a xanthine oxidase inhibitor, on hepatic injury in the bile duct-ligated rat
33. Evidence for accelerated generation of hydroxyl radicals in experimental obstructive jaundice of rats
34. Bile acid-induced rat hepatocyte apoptosis is inhibited by antioxidants and blockers of the mitochondrial permeability transition
35. Nonionic detergents induce dimerization among members of the Bcl-2 family
36. Bax in murine thymus is a soluble monomeric protein that displays differential detergent-induced conformations
37. Structure of Bax: Coregulation of dimer formation and intracellular localization
38. Nuclear DNA fragmentation and expression of Bcl-2 in primary biliary cirrhosis
39. Hepatocytes in bile duct-ligated rat express Bcl-2
40. The Bcl-2 protein family: Arbiters of cell survival
41. Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis
42. Bcl-2 inhibition of neural death: Decreased generation of reactive oxygen species
43. Bcl-2 functions in an antioxidant pathway in apoptosis
44. Double identity for proteins of the Bcl-2 family
45. Inhibition of caspases inhibits the release of apoptotic bodies: Bcl-2 inhibits the initiation of formation of apoptotic bodies in chemotherapeutic agent-induced apoptosis
46. Modulation of apoptosis-associated genes bcl-2, bcl-x, and bax during rat liver regeneration
47. Development and initial application of an in vitro model of apoptosis in rodent cholangiocytes
48. Posttranscriptional regulation of mRNA levels in rat liver associated with deoxycholic acid feeding
49. Modulation of steady-state messenger RNA levels in the regenerating rat liver with bile acid feeding
50. Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas
51. Cathepsin B contributes to bile salt-induced apoptosis of rat hepatocytes
52. Bile salt-induced apoptosis of hepatocytes involves activation of protein kinase C
53. Increases of intracellular magnesium promote glycodeoxycholate-induced apoptosis in rat hepatocytes
54. Phosphoinositide 3-kinase, but not mitogen-activated protein kinase, pathway is involved in hepatocyte growth factor-mediated protection against bile acid-induced apoptosis in cultured rat hepatocytes
55. GUDC inhibits cytochrome c release from human cholangiocyte mitochondria
56. Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis
57. L, decreases the lifetime of planar phospholipid bilayer membranes at subnanomolar concentrations
58. Tauroursodeoxycholate prevents mitochondrial membrane perturbation induced by recombinant Bax protein
59. Ursodeoxycholic acid protects primary mouse hepatocytes in a physiologic model of Fas ligand induced apoptosis
60. An NO derivative of ursodeoxycholic acid protects against-mediated liver injury by inhibiting caspase activity
61. Is ursodeoxycholic acid an antiapoptotic drug?
62. Tauroursodeoxycholate prevents biliary protein excretion induced by other bile salts in the rat
63. Tauroursodeoxycholate and tauro-beta-muricholate exert cytoprotection by reducing intrahepatocyte taurochenodeoxycholate content
64. Kinetics of hepatic bile acid handling in cholestatic liver disease: Effect of ursodeoxycholic acid
65. Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment
66. Serum bile acids in primary biliary cirrhosis: Effect of ursodeoxycholic acid therapy
67. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis
68. The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis
69. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis
70. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis
71. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: A placebo-controlled trial
72. Ursodiol for primary sclerosing cholangitis
73. Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease
74. Effects of ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdr2 P-glycoprotein gene
75. 2+ mechanisms defective in cholestasis
76. Involvement of microtubules in the swelling-induced stimulation of transcellular taurocholate transport in perfused rat liver
77. Role of bile salt hydrophobicity in hepatic microtubule-dependent bile salt secretion
78. Tauroursodeoxycholic acid activates protein kinase C in isolated rat hepatocytes
79. Mitogen-activated protein kinases mediate the stimulation of bile acid secretion by tauroursodeoxycholate in rat liver
80. Regulated exocytosis
81. Mechanisms and regulation of bile secretion
82. 2+ signals in isolated rat hepatocytes
83. 2+ and activates phosphorylase A in isolated hepatocytes
84. Control by signaling modulators of the sorting of canalicular transporters in rat hepatocyte couplets: Role of the cytoskeleton
85. Ursodeoxycholic acid inhibits glucagon-induced cAMP formation in hamster hepatocytes: A role for PKC
86. Hepatocellular protein kinase C activation by bile acids: Implications for regulation of cholesterol 7 alpha-hydroxylase
87. Inhibition of bile flow, hepatobiliary exocytosis, and Mrp-2-insertion into the canalicular membrane by taurolithocholic acid is reversed by taurourosodeoxycholic acid in the perfused rat liver
88. Tauroursodeoxycholate (TUDCA) protects against redistribution of multidrug resistance protein 2 (Mrp2) and disruption of F-actin caused by taurolithocholate (TLC); a study in isolated rat hepatocyte couples
89. Catabolites of cholesterol synthesis pathways and forskolin as activators of the farnesoid X-activated nuclear receptor
90. Identification of a nuclear receptor for bile acids
91. Bile acids: Natural ligands for an orphan nuclear receptor
92. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses?
93. Behavioral pathology induced by repeated systemic injections of 3-nitropropionic acid mimics the motoric symptoms of Huntington's disease
94. Effects of chronic MPTP and 3-nitropropionic acid in non-human primates
95. A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease
96. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity
97. An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids
98. Colchicine protects mice from the lethal effect of an agonistic anti-Fas antibody
99. Bisindolylmaleimide VIII facilitates Fas-mediated apoptosis and inhibits T cell-mediated autoimmune diseases